Biotech Debt is Through the Roof; Where to find value


An article was recently published by S&P Global Market Intelligence which discusses pharmaceutical and biotechnology debt issuance soaring in 2020, and the possibility that it may fuel mergers & acquisitions activity in the space. 

The article states “Pharmaceutical and biotechnology companies in the U.S. have already issued more debt in 2020 than in all of 2019, raising cash holdings to $26.92 billion as compared to $23.34 billion last year, according to an analysis by S&P Global Market Intelligence.”

The article further states, “Three companies lead the pack in debt issuances: Amgen Inc., Pfizer Inc. and Merck & Co. Inc., issuing $9 billion, $5.25 billion and $4.5 billion, respectively.”

One company to look at in the space is Glucose Health, Inc. (OTC Pink: GLUC), which manufacturersnutritional beverages for the adult-diabetic nutrition consumer retail category under the registered trademark GLUCODOWN®. 

Today…more than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).

The run was completed in September and sent to their largest national retail partners including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and online at (NASDAQ: AMZN) to meet growing consumer demand.  

Despite being on the shelves of national pharmacy retailers like Walmart (NYSE: WMT) and CVS Health (NYSE: CVS), GLUC is trading below a $30 million valuation.  If M&A Activity does heat up in the space, GLUC could be a serious take-out prospect.

GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.

See their latest GLUCODOWN® products here;

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4? 

Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list. 

About is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. has motivation by means of either self-marketing or has been compensated by or for a company or companies discussed in this article. has been compensated twelve thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the website.